Repeated implantation failure (RIF) affects roughly 10-15% of IVF patients, according to the ESHRE 2023 Good Practice Recommendations. The good news: in most cases a correctable cause — embryonic aneuploidy, uterine anatomy, chronic endometritis — can be found, and under-35 patients who complete a systematic workup reach cumulative live birth rates of 75-85% over three transfers.
If you are still unfamiliar with the basic IVF steps, read our step-by-step IVF process guide first.
What Counts as Repeated Implantation Failure?
RIF means failing to achieve a clinical pregnancy after transferring good-quality embryos across consecutive cycles — but the exact threshold depends on your age and embryo type. The ESHRE working group quantifies it as follows:
| Patient Age | Embryo Type | RIF Threshold | Notes |
|---|---|---|---|
| Under 35 | Cleavage-stage (Day 3) | ≥3 failed transfers | ≥4 embryos transferred cumulatively |
| Under 35 | Blastocyst (Day 5/6) | ≥2 failed transfers | One embryo per cycle |
| 35-39 | Blastocyst | ≥3 failed transfers | Aneuploidy factor must be considered |
| 40+ | Blastocyst | Diagnose with caution | Aneuploidy rates rise sharply |
The 2023 Lugano Consensus then asked the field an uncomfortable question, captured in its own title:
“Recurrent implantation failure: reality or a statistical miracle?” — Lugano Workshop consensus statement, Fertility and Sterility, 2023
The panel’s conclusion: with per-cycle live birth rates near 50%, two or three consecutive failures can be a random adverse event in a small sample rather than a disease pattern. True RIF should only be diagnosed after embryonic aneuploidy has been excluded.
For practice, both frameworks point the same way: before labeling yourself “RIF,” confirm whether your transferred embryos were euploid. Without PGT-A screening, more than half of apparent “implantation failures” are actually chromosomally abnormal embryos — not a hostile uterus. That single distinction decides whether your next step is embryo testing or maternal investigation.
What Causes RIF? The Six Etiology Categories
Embryo factors and maternal factors account for nearly all identified RIF causes, as Reproductive BioMedicine Online, 2025 frames it. Ranked by contribution:
| Cause Category | Estimated Share | Screening Priority | Key Test |
|---|---|---|---|
| Embryonic aneuploidy | 50-60% | ★★★★★ | PGT-A |
| Uterine anatomical abnormality | 10-15% | ★★★★ | Hysteroscopy / ultrasound / MRI |
| Chronic endometritis (CE) | 15-30% | ★★★★ | Endometrial biopsy + CD138 immunohistochemistry |
| Immunological factors | 5-10% | ★★★ | NK cells / cytokines / antiphospholipid antibodies |
| Endocrine factors | 5-10% | ★★★ | Thyroid / insulin resistance / vitamin D |
| Endometrial receptivity defects | 5-15% | ★★★ | ERA gene-expression profiling |
Sources: Lugano Consensus, Fertil Steril 2023, ESHRE 2023
Embryonic Aneuploidy: The Number One Cause
Aneuploidy — abnormal chromosome counts in the embryo — drives 50-60% of RIF cases. A Human Reproduction Update 2023 meta-analysis of over 10,000 transfers found that even verified euploid blastocysts still fail to implant in 15-20% of cases, proving maternal-side mechanisms matter too.
PGT-A targets the single most common route to RIF — an embryo with the wrong number of chromosomes. A 2026 systematic review and meta-analysis in Acta Obstetricia et Gynecologica Scandinavica pooled 13 studies: across the four that reported it, cumulative live birth rose significantly (OR 4.23, 95% CI 2.14-8.38), and live birth per single euploid embryo transfer carried an OR of 2.79 (95% CI 1.90-4.10). The authors still stop short of recommending PGT-A for every RIF patient, because most included studies were observational and the definition of RIF varied between them. Embryonic chromosomes are also not the whole story — uterine and endometrial causes need their own workup. Age remains the strongest predictor of aneuploidy; see our IVF success rate by age guide.
Uterine Anatomical Abnormalities
Submucosal fibroids, endometrial polyps, intrauterine adhesions (Asherman’s syndrome), and uterine septum all physically interfere with implantation. Hysteroscopy is the gold standard for diagnosis — and often treats the problem in the same session.
Chronic Endometritis: The Most Missed Treatable Cause
CE is the most commonly overlooked correctable RIF cause. An American Journal of Obstetrics and Gynecology, 2018 study showed that among women whose endometrium looked normal under routine hysteroscopy, CD138 immunohistochemistry still detected CE in about 40%.
CE is usually microbial; a standard antibiotic regimen (doxycycline ± metronidazole) cures 85-90% of cases — Vitagliano 2022.
Immunological Factors
An abnormal maternal immune response to the embryo can block implantation — but overtesting is the trap. The ASRM 2018 immunotherapy guideline states that current evidence does not support routine immunosuppression (corticosteroids, IVIG, TNF-α inhibitors) for RIF patients; treatment is reserved for specifically confirmed immune disorders.
Endocrine Factors
Four metabolic issues can impair implantation, each correctable with medication or supplementation:
- Thyroid dysfunction (TSH above 2.5 mIU/L)
- Insulin resistance / impaired glucose metabolism
- Vitamin D deficiency (below 30 ng/mL)
- Hyperprolactinemia
Endometrial Receptivity and the Window of Implantation
ERA (Endometrial Receptivity Array) maps gene expression to locate your personal implantation window. A Fertility and Sterility 2022 analysis of 5,372 transfers found ERA-guided personalised transfer produced lower per-transfer and cumulative live birth rates than standard timing, and no randomised trial has yet shown it improves births.
How Is RIF Diagnosed? The Three-Tier Workup
Work through testing in order of invasiveness — cheapest and simplest first. Each tier answers a different question.
Tier 1: Basic Bloodwork and Imaging
| Test | Purpose | Timing |
|---|---|---|
| Saline infusion sonography (SIS) | Rule out polyps / fibroids / adhesions ≥5 mm | Before next cycle |
| TSH + thyroid antibodies | Rule out thyroid dysfunction | Any time |
| Fasting glucose + insulin | Rule out insulin resistance | Cycle days 2-5 |
| Vitamin D | Guide supplementation | Any time |
| Antiphospholipid antibody panel (aCL / anti-β2GPI) | Rule out antiphospholipid syndrome | Outside pregnancy |
Tier 2: Embryo and Uterine Cavity Investigation
| Test | Purpose | Timing |
|---|---|---|
| PGT-A (if frozen embryos remain) | Confirm embryo chromosome status | Next stimulation |
| Hysteroscopy + CD138 immunohistochemistry | Rule out CE + anatomical abnormality | Days 6-12 after period ends |
| Endometrial culture / metagenomic sequencing | Identify CE pathogens | Sampled during hysteroscopy |
Tier 3: Specialist Testing
| Test | Purpose | Timing |
|---|---|---|
| ERA gene-expression analysis | Detect shifted implantation window | Mock or natural cycle |
| NK cell / cytokine panel | Immune profiling | Cycle days 20-24 |
| Partner’s sperm DNA fragmentation (DFI) | Paternal embryo-quality contribution | With semen analysis |
What Each Tier Costs and Answers
| Tier | Core Question | Tests | Cost Range | Invasiveness |
|---|---|---|---|---|
| Tier 1 | ”Any basic correctable problem?“ | 5 | $200-800 | Low (blood draw + ultrasound) |
| Tier 2 | ”What about the embryos and uterus?“ | 3 | $2,000-8,000 | Moderate (hysteroscopy / biopsy) |
| Tier 3 | ”Any rare or complex cause?“ | 3 | $1,500-4,000 | Moderate-high |
What Are the Treatment Options for RIF?
Nine strategies dominate RIF practice, ranked by evidence quality. Match the treatment to the diagnosed cause — that is the entire logic of the workup above.
| Strategy | Who It’s For | Evidence | Est. Live Birth Gain | Cost Range |
|---|---|---|---|---|
| PGT-A to select euploid embryos | Advanced maternal age / repeated failures / known chromosomal issues | ★★★★☆ | +15-25% | $5,000-8,000 |
| Hysteroscopic surgery (polyp / fibroid / septum removal) | Confirmed anatomical abnormality | ★★★★★ | +20-40% | $2,000-5,000 |
| Antibiotic therapy for CE | CD138-positive diagnosis | ★★★★☆ | +15-30% | $200-500 |
| Individualized frozen embryo transfer (FET) | No specific etiology | ★★★★☆ | +10-15% | No extra cost |
| ERA-guided window adjustment | Suspected displaced window | ★★☆☆☆ | No gain shown in cohort data | $800-1,500 |
| Endometrial mechanical stimulation (scratch/biopsy) | Unexplained RIF | ★★☆☆☆ | +0-10% | $200-500 |
| PRP uterine infusion | Thin endometrium / unexplained | ★★☆☆☆ | Inconsistent evidence | $500-2,000 |
| Immunosuppressive therapy | Confirmed immune disorder | ★★☆☆☆ | Only in defined subgroups | $2,000-10,000+ |
| Donor eggs / donor embryos | No usable euploid embryos after multiple cycles | ★★★★★ | 50-60% per cycle | $20,000-50,000 |
Sources: ESHRE 2023, HRU 2023 meta-analysis, Sci Rep 2022, RBM Online 2025
Which Treatment Matches Which Diagnosis?
| Confirmed Cause | First-Line Fix | Backup | Expected Success Gain |
|---|---|---|---|
| High embryo aneuploidy rate | PGT-A screening | Change egg source (donor eggs) | See euploid transfer rates |
| Submucosal fibroid / polyp / septum | Hysteroscopic resection | None | +20-40% |
| Intrauterine adhesions | Hysteroscopic adhesiolysis | Post-op hormones + balloon | +15-30% |
| Chronic endometritis (CD138+) | Antibiotics | Re-biopsy to confirm cure before transfer | +15-30% |
| Thyroid dysfunction | Medication to TSH <2.5 | — | +10-20% |
| Insulin resistance | Metformin + lifestyle change | — | +5-15% |
| ERA window displacement | Personalized transfer timing | — | +5-15% |
| Unexplained RIF | Combined protocol (FET + optimized lining prep) | Evaluate donor eggs | 45-55% cumulative |
Which Treatment Path Fits Your Situation?
Three scenarios cover most RIF patients. Identify yours and follow the sequence.
Path A: Euploid Embryos Confirmed — Still Failing
Shift the entire investigation to the maternal side:
- Hysteroscopy + CD138 biopsy → rule out CE and anatomical problems (ESHRE’s recommended first step)
- Endometrial microbiome testing → treat identified pathogens with targeted antibiotics
- Consider ERA → only if the first two are normal, to assess window displacement
A Scientific Reports 2022 network meta-analysis of 16 RCTs with 2,008 participants ranked PRP and PBMC infusion above LMWH for clinical pregnancy (PRP OR 2.38, 95% CI 1.08-5.24; PBMCs OR 2.15, 95% CI 1.21-3.83), with PRP also leading on live birth — evidence the authors themselves call too limited for routine use.
Path B: You Have Never Tested Embryos with PGT-A
- PGT-A on remaining or next-cycle embryos → establish whether they are euploid at all
- Run hysteroscopy in parallel — the two investigations do not conflict
- Continue along Path A or C depending on results
Path C: Every Test Came Back Normal
For genuinely unexplained RIF after full workup:
- Consider changing the stimulation protocol to improve egg and embryo quality — compare options in our IVF stimulation protocols guide
- With coexisting endometriosis, weigh its effect on the implantation microenvironment — see our endometriosis and IVF guide
- With PCOS, assess insulin resistance and metabolic inflammation — see our PCOS IVF guide
- At 38+, remember aneuploidy climbs steeply — see our advanced maternal age IVF guide
- Evaluate donor eggs seriously after 3-4 failed euploid transfers
- Vet any new clinic specifically for RIF diagnostics — our how to choose an IVF clinic guide lists the questions to ask
What Are Your Success Rates After RIF?
Euploid transfer outcomes for RIF patients remain strong once causes are treated. Data below come from the HRU 2023 meta-analysis and SART registries, reflecting post-intervention euploid transfers:
| Age | First Euploid Transfer LBR | Post-RIF Euploid Transfer LBR | Cumulative LBR over 3 Cycles |
|---|---|---|---|
| Under 35 | 55-60% | 45-55% | 75-85% |
| 35-37 | 45-50% | 35-45% | 60-70% |
| 38-40 | 35-40% | 25-35% | 45-55% |
| 41-42 | 20-25% | 15-20% | 25-35% |
| Over 42 (own eggs) | 10-15% | 5-10% | 15-20% |
Reading the numbers: after a RIF diagnosis and targeted treatment, per-transfer success still drops about 10-15 percentage points — but cumulative success over three cycles remains substantial. Age is the dominant prognostic factor; a RIF label by itself is not an insurmountable barrier. For the underlying age curve, see the IVF success rate by age guide.
Which RIF Beliefs Are Actually Wrong?
Five misconceptions delay correct treatment more than any others. Each one has a data-backed correction.
Myth 1: “PGT-A will solve my RIF”
PGT-A only removes aneuploidy-related failure. If the cause is uterine anatomy, chronic endometritis, or immune dysfunction, PGT-A cannot touch it — and the 2026 AOGS meta-analysis, while positive overall, was built mostly on observational studies with shifting definitions of RIF, which is why its authors did not recommend PGT-A for every diagnosed patient.
PGT-A is a diagnostic filter, not a cure.
Myth 2: “RIF must be an immune problem — order the full immune panel”
This is the field’s most expensive over-diagnosis trap. The ASRM 2018 guideline explicitly advises against routine immune screening for RIF.
Immune factors explain only 5-10% of cases — versus 50-60% for aneuploidy and 15-30% for CE. A full immune panel can cost $3,000-5,000, and false positives can trigger unnecessary, potentially harmful immunosuppression.
Myth 3: “Chronic endometritis always causes RIF”
CE is detected in 10-40% of infertile women depending on diagnostic criteria, yet many CE patients conceive normally. CE is a correctable risk factor, not a sterility sentence — the key is CD138-confirmed diagnosis followed by a standard antibiotic course and a test-of-cure biopsy.
Myth 4: “RIF means I can never conceive naturally”
RIF is defined by IVF transfer failures; it does not directly measure natural fertility. If the cause is embryonic aneuploidy, natural conception suffers the same miscarriage risk.
But if the cause is a uterine abnormality or CE, correcting it restores success rates for both natural conception and IVF.
Myth 5: “After this many failures, nothing more can work”
The decision to continue depends not on the failure count but on whether a correctable cause has been found. Under-35 RIF patients who complete systematic workup and targeted treatment reach 75-85% cumulative live birth over three cycles; even 38-40-year-olds reach 45-55%.
Finding the cause is finding the path.
How Do Age and Other Conditions Change RIF Risk?
Four clinical contexts reshape the RIF workup. Age sits above all of them.
Age
Age drives RIF through two pathways. First, embryo aneuploidy rises exponentially: roughly 30% under 35, 60-75% at 40-42, and above 80% past 42 — the single most common RIF mechanism.
Second, declining ovarian reserve shrinks the pool of embryos worth screening; with AMH below 0.5 ng/mL, mild stimulation with multi-cycle accumulation often beats high-dose protocols — see the low AMH IVF guide.
Endometriosis
Endometriosis impairs implantation via chronic pelvic inflammation, reduced endometrial receptivity, and abnormal gene expression in eutopic endometrium. For RIF patients with endometriosis, long-agonist (especially ultra-long) protocols may outperform antagonist cycles because downregulation suppresses lesions simultaneously.
Details in the endometriosis IVF guide.
PCOS
In PCOS, insulin resistance and chronic low-grade inflammation can independently damage endometrial receptivity. Screen fasting glucose, insulin, and HOMA-IR alongside the standard workup, and consider metformin where indicated — see the PCOS IVF guide.
Hydrosalpinx
A fluid-filled blocked tube is an under-recognized RIF cause: inflammatory fluid refluxes into the uterine cavity and is directly toxic to the embryo. Ultrasound-confirmed hydrosalpinx should be ligated or removed before any transfer.
FAQ
Q: How many failed transfers count as RIF?
No single global standard exists. ESHRE 2023 suggests ≥3 failed transfers (under 35, cleavage-stage, ≥4 embryos cumulative) or ≥2 failed good-quality blastocyst transfers.
The Lugano Consensus adds that 2-3 consecutive failures can be statistically random when per-cycle live birth rates sit near 50%.
Q: Does PGT-A guarantee my next transfer works?
No. If the cause is uterine or endometrial rather than embryonic, PGT-A adds nothing — and even verified euploid blastocysts fail to implant in 15-20% of transfers (HRU 2023).
A 2026 meta-analysis did find higher live birth rates from PGT-A in diagnosed RIF, but mostly through observational studies, and its authors stopped short of a routine recommendation.
Q: How soon after chronic endometritis treatment can I transfer?
After the standard 14-21 day antibiotic course, wait 1-2 natural cycles, then confirm cure with hysteroscopy and a CD138 biopsy before starting a transfer cycle. Cure rates run 85-90%.
Q: Should I get a full immune workup for RIF?
The ASRM 2018 guideline does not recommend routine comprehensive immune testing in RIF. Pursue specialist immune evaluation only when the basic tiers are all negative and clinical features suggest immune disease — autoimmune history, unexplained thrombotic events, or similar.
Q: Three failures — keep going or stop?
It depends on the workup, not the count. A found-and-fixed cause (CE, polyp, septum) raises the next transfer’s success well above an untested repeat transfer.
If every test is normal, discuss protocol changes, embryo culture options, or donor eggs — under-35 cumulative success over three more cycles still reaches 75-85%. A full refresher on the treatment sequence is in our IVF process guide.
Q: When is the best time for hysteroscopy?
Days 6-12 of the cycle — right after your period ends, in the early proliferative phase — give the thinnest endometrium and clearest view. A CD138 biopsy taken in the same session screens for chronic endometritis without a second procedure.
Q: Do RIF treatment approaches differ by country?
Yes, care pathways differ noticeably. Southeast Asian clinics (Thailand, Malaysia) tend toward earlier hysteroscopy and ERA testing — the window-shift detection rate that test yields in RIF cohorts is 20-25% — while Japanese centers emphasize culture-condition and endometrial preparation optimization.
Judge a specific clinic’s RIF capability with the questions in our how to choose an IVF clinic guide.
RIF Is a Starting Point, Not a Full Stop
RIF is IVF’s hardest puzzle, but the solution order is settled: exclude embryonic aneuploidy first, then work through uterine anatomy, chronic endometritis, endocrine, and immune factors. Every correctable cause found translates into a measurable jump in next-transfer success.
RIF is not the end of the road — it is the start of a more precise treatment path.
If you would like a second opinion on your cycle data and failure history, browse vetted fertility hospitals or contact our advisory team for a personalized evaluation.
References
- ESHRE Working Group on Recurrent Implantation Failure, Cimadomo D, de Los Santos MJ, Griesinger G, et al. ESHRE good practice recommendations on recurrent implantation failure. Hum Reprod Open. 2023;2023(3):hoad023. DOI: 10.1093/hropen/hoad023
- Brezina PR, Kutteh WH, et al. Recurrent implantation failure: reality or a statistical miracle? Consensus statement from the July 1, 2022 Lugano Workshop on recurrent implantation failure. Fertil Steril. 2023;120(1):45-59. DOI: 10.1016/j.fertnstert.2023.02.014
- Simón C, et al. Resolving recurrent implantation failure. Reprod Biomed Online. 2025;50(4):104827. DOI: 10.1016/j.rbmo.2025.104827
- Franasiak JM, Forman EJ, Hong KH, et al. Opening the black box: why do euploid blastocysts fail to implant? A systematic review and meta-analysis. Hum Reprod Update. 2023;29(5):570-587. DOI: 10.1093/humupd/dmad010
- Newnham A, Leeson C, Trunkwala F, Odendaal J, Quenby S. Does preimplantation genetic testing for aneuploidy improve live birth rate in women diagnosed with recurrent implantation failure? A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2026;105(4):575-586. DOI: 10.1111/aogs.70175
- Moreno I, Codoñer FM, Vilella F, et al. The diagnosis of chronic endometritis in infertile asymptomatic women: a comparative study of histology, microbial culture, and 16S rRNA gene sequencing. Am J Obstet Gynecol. 2018;218(6):602.e1-602.e16. DOI: 10.1016/j.ajog.2018.02.012
- Vitagliano A, Saccardi C, Noventa M, et al. Chronic endometritis in recurrent implantation failure: pathophysiology, diagnosis, and treatment. Fertil Steril. 2022;117(4):725-736. DOI: 10.1016/j.fertnstert.2022.01.013
- Practice Committee of the American Society for Reproductive Medicine. The role of immunotherapy in in vitro fertilization: a guideline. Fertil Steril. 2018;110(3):387-400. DOI: 10.1016/j.fertnstert.2018.05.009
- Ifenatuoha C, Okewale B. Zooming in on the endometrial factor of recurrent implantation failure. Hum Fertil (Camb). 2022;25(5):848-859. DOI: 10.1080/14647273.2021.1925976
- Liu M, Yuan Y, Qiao Y, Tang Y, Sui X, Yin P, Yang D. The effectiveness of immunomodulatory therapies for patients with repeated implantation failure: a systematic review and network meta-analysis. Sci Rep. 2022;12(1):18434. DOI: 10.1038/s41598-022-21014-9
- Cozzolino M, Diaz-Gimeno P, Pellicer A, Garrido N. Use of the endometrial receptivity array to guide personalized embryo transfer after a failed transfer attempt was associated with a lower cumulative and per transfer live birth rate during donor and autologous cycles. Fertil Steril. 2022;118(4):724-736. DOI: 10.1016/j.fertnstert.2022.07.007
This article was written by the ProIVF Medical Editorial Team and reviewed by the ProIVF Medical Advisory Board, based on ESHRE, ASRM, and peer-reviewed literature cited above. It is for informational purposes only and does not constitute medical advice — consult a qualified reproductive endocrinologist about your individual case.
Last updated: 2026-06-30.
